|
SCD is a pharmaceutical company established in 1943 that manufactures and sells prescription drugs, including antibiotics, cardiovascular treatments, gastrointestinal medications, and ophthalmic products. The company operates through a single business segment and produces its products at a facility in Hwaseong, South Korea. Its subsidiary Optus Pharmaceutical manufactures ophthalmic solutions and eye drops, while SCD US, INC and SCD BIOTECH, LLC handle export certifications and approvals in North America, and SCD JAPAN manages pharmaceutical wholesale in Japan. SCD exports finished pharmaceuticals to markets including Vietnam, Hong Kong, Singapore, the United States, and Europe. The company has established supply and distribution partnerships with Breckenridge Pharmaceutical, Glenmark, Omnivision, SENJU Pharmaceutical, Apotex, Fresenius Kabi, and Daiichi Sankyo. Its research and development portfolio includes the Aflibercept biosimilar SCD411 for macular degeneration, MRI contrast agents, and oral generic versions of diabetes and obesity treatments such as Rybelsus and Wegovy Oral. Summarised from the company's own disclosures, fiscal year ended Jun 2026 |
Industry Drug Manufacturers - General | Homepage scd.co.kr |
| Sector Healthcare | IR page — | |
|
Tags
ophthalmic drugs, antibiotics, cardiovascular drugs, gastrointestinal drugs, biosimilars, contrast agents, oral generics, diabetes treatment, obesity treatment, macular degeneration, Optus Pharmaceutical, SCD US INC, SCD BIOTECH LLC, SCD JAPAN, SCD411, SCD311, SCD0503, SCD0506, SCD0501, SCD0502, SCD0504, Aflibercept, Rybelsus, Wegovy Oral, S-Pass
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | — |
| Market cap (USD) | — |
| P/E | — |
| PEG | — |
| P/BV | — |
| P/S | — |
| P/OCF | — |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 1.9% |
| ROI | 1.9% |
| ROIC | 2.9% |
| Profit margin | 2.3% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | -3.4% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | — |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 33.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 231.805B | 210.924B | 192.669B | 177.335B | 167.275B | 166.862B | 186.602B | 159.96B | 161.112B | 147.373B | 132.062B | 118.924B | 104.543B |
| Net profit | 5.262B | -10.916B | -10.383B | 5.838B | -16.555B | -965.677M | 10.452B | 8.754B | 15.058B | 8.712B | 11.628B | 11.848B | 8.724B |
| Free cash flow | -36.353B | 4.748B | 16.662B | -3.252B | -22.589B | -5.429B | 24.009B | 13.482B | 25.378B | 13.656B | 8.688B | 10.833B | 11.657B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 38.3B | 38.9B | 36.8B | 38.5B | 36.2B | 34.2B | 37.9B | 34.4B | 58.1B | 55.3B |
| ↳ YoY growth | +18.2% | +1.6% | -5.4% | +4.7% | -6.0% | -5.5% | +10.8% | -9.3% | +68.9% | -4.9% |
| ↳ 5y CAGR | +3.6% | +2.9% | +2.3% | -2.2% | -0.5% | -1.3% | +8.6% | +8.8% | ||
| Borrowings, current (KRW) | 6.98B | 2.34B | 13B | 13.6B | 2.01B | 21.6B | 2.76B | 32.2B | 28.3B | 44.8B |
| Borrowings, non-current (KRW) | — | 3B | — | — | 20B | 26.1B | 40B | 16B | 17B | 0.00 |
| Bonds payable (KRW) | — | — | 10.8B | 11.2B | — | 26.1B | 27.8B | 0.00 | 0.00 | — |
| Lease liabilities (KRW) | — | — | — | 2.78B | 5.06B | 3.9B | 6.01B | 5.4B | 4.65B | 4.02B |
| Cash and deposits (KRW) | 48.6B | 61.9B | 51.5B | 60.3B | 58.9B | 49.1B | 22.1B | 40.4B | 106B | 95.9B |
| Intangible assets (KRW) | 13.1B | 20B | — | 30.2B | — | — | — | 96.3B | — | 130B |
| Net debt (borrowings + leases - cash) (KRW) | -41.6B | -56.6B | -38.5B | -43.9B | -31.9B | 2.43B | 26.7B | 13.2B | -55.6B | -47.1B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 17.8B | 28.6B | 25B | 30.6B | 3.25B | -7.71B | 13.3B | 23.4B | 21.8B | 9.79B |
| Purchases of property, plant and equipment (KRW) | -4.11B | -3.25B | -11.6B | -6.59B | -8.68B | -14.9B | -16.5B | -6.77B | -17B | -46.1B |
| Purchases of intangible assets (KRW) | -5B | -7.6B | -8.41B | -3.57B | -3.12B | -14.4B | -30B | -15.2B | -24.3B | -13.4B |
| Change in receivables (cash effect) (KRW) | — | — | — | — | — | -2.35B | -3.47B | 3.21B | -23.5B | — |
| Change in inventories (cash effect) (KRW) | -2.33B | -3.46B | -1.57B | -1.62B | -4B | -2.28B | -5.29B | -5.75B | -5.07B | -15.8B |
| Change in payables (cash effect) (KRW) | — | — | — | — | — | 4.59B | -3.69B | -6.3B | 13.2B | 9.47B |
| Dividends paid (cash effect) (KRW) | -2.02B | -2.06B | -2.07B | -2.07B | -2.07B | -968M | -968M | -881M | -890M | -4.65B |
| Share buybacks (cash effect) (KRW) | — | — | — | — | -2.02B | 0.00 | -5.96B | 0.00 | 0.00 | 0.00 |
| Interest paid (cash effect) (KRW) | -124M | -198M | -222M | -222M | -173M | -378M | -1.37B | -2.85B | -128M | -138M |
| Income taxes paid (cash effect) (KRW) | -6.14B | -4.28B | -3.03B | -2.03B | -8.15B | -3.28B | -2.43B | -1.43B | -2.63B | -22B |
| Share-based compensation (KRW) | — | — | — | — | — | 0.00 | 0.00 | 81.4M | 519M | -503M |
| Operating cash flow before change in receivables (KRW) | — | — | — | — | — | -5.36B | 16.7B | 20.2B | 45.3B | — |
| Free cash flow (OCF - PPE - intangibles) (KRW) | 8.65B | 17.8B | 5.07B | 20.4B | -8.55B | -37B | -33.3B | 1.45B | -19.5B | -49.8B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | 15.8B | 29.4B | 14.1B | 19.5B | 7.87B | -6.43B | 9.4B | -5.63B | -5.43B | 12.2B |
| Comprehensive income to owners (KRW) | 8.97B | 21.4B | 8.25B | 10.4B | -823M | -12.5B | 6.41B | -11.9B | -11.1B | 5.2B |
| Provision for credit losses (KRW) | — | — | — | — | — | -166M | 246M | 77.7M | 266M | 23.8M |
| Credit cost ratio (credit losses / average receivables) (%) | — | — | — | — | — | 0.5% | 0.7% | 0.2% | 0.6% | 0.0% |
| Reported | Jun 18, 2018 | Jun 18, 2018 | Mar 29, 2019 | Nov 16, 2020 | Mar 15, 2021 | Mar 20, 2024 | Mar 20, 2024 | Aug 14, 2024 | May 15, 2025 | Oct 8, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding SCD
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.



























